Joinn Laboratories(China)Co (603127) Fair Value & Analysis
Healthcare · CN · Market cap 38.1B CNY (≈ $5.7B) · ISIN CNE100002W27
What is Joinn Laboratories(China)Co really worth?
A solid business, but trading 366% above our fair value of ¥9.22.
Strengths
Risks
For context
Fair value as of: Sep 5, 2026
From 23 valuation models · updated today
Share price −7.3% over the past month.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
What matters now
- The price sits above even our optimistic bull case (¥10.04). The favourable scenario is already priced in.
- Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 5, 2026.
How to read this chart
60‑month range ¥12.46 – ¥87.11 · fair‑value band ¥7.24 – ¥10.04 · the ¥42.94 price screens above the ¥9.22 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 5, 2026.
Analysis
Joinn Laboratories(China)Co (603127) currently trades at ¥42.94, while our model-based Fair Value estimate is ¥9.22, implying the stock looks roughly 365.8% overvalued today. The Quality Score stands at 60/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of ¥13.89 per share, and 0 of the 23 models we run sit above the ¥42.94 price. Bear case: the Multiples group reads lowest at ¥8.03, and 23 of the 23 models stay below the price. Evidence for this calculation is medium.
Over the trailing twelve months, Joinn Laboratories(China)Co generated revenue of 1.7B CNY at a net margin of 29.4%. Revenue grew 10.0% year over year. It earns a return on equity of 5.9%. The balance sheet holds a net cash position of 904M CNY. Fundamentals as of Sep 5, 2026
Our scenario range runs from ¥7.24 (bear case) to ¥10.04 (bull case); at ¥42.94, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 7% below its 52-week high and 132% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −54% fair-value upside, at −79%, 603127 screens richer than that median.
Fair Value models
This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly ¥0.3722 per share, which is 4.0 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.
All 23 models by family
Widest divergence: Growth Earnings (¥13.89) versus Dividend Discount (¥0.5700). Highest evidence: FCF DCF (74).
Notify me when 603127 reaches fair value
Put 603127 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Free, no payment details. Unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Sep 5, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 60 · Market factors (momentum, volatility) 67
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.
About the company
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models.
Full company description
Joinn Laboratories(China)Co.,Ltd. provides preclinical and non-clinical services in the United States, the People's Republic of China, and internationally. It operates through three segments: Non-Clinical Studies Services; Clinical Trial and Related Services; and Sales of Research Models. The Non-Clinical Studies Services segment offers drug safety assessment, drug metabolism and pharmacokinetics DMPK studies, and pharmacology and efficacy studies. Its Clinical Trial and Related Services segment provide clinical contract research organization services, co-managed phase I clinical research units, and bioanalytical services. The Sales of Research Models segment engages in the design, production, breeding, and sale of research models, including non-human primates and rodents. The company also offers cell-based assay (CBA) services. In addition, it offers drug quality research and testing services for protein drugs, vaccines, gene and cell therapy products, and provides customized solutions for early-stage drug discovery, screening, and mechanism research. Joinn Laboratories(China)Co.,Ltd. was incorporated in 1995 and is headquartered in Beijing, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Joinn Laboratories(China)Co reported revenue of 1.7B CNY in FY2025 versus 1.5B CNY in FY2021, a compound +2.2%/yr. Reported net income was 298M CNY in FY2025, compounding −14.5%/yr from FY2021.
of which total revenue +32.3 % · buybacks/dilution −5.2 %
Annual growth per factor. These are factors, not summands: multiplied they give the EPS growth rate, added they do not quite. Start and end points are 3-year averages (details on hover).
603127 screens 366% overvalued. Compare with Thermo Fisher Scientific Inc →
Peer Group
Diagnostics & Research · 130 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Diagnostics & Research median · lower = cheaper
Strength profile in five axes (Snowflake)
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Sep 5, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Thermo Fisher Scientific Inc TMO | $630.70 | $308.19 | −51% |
| Danaher Corporation DHR | $215.68 | $103.88 | −52% |
| WuXi AppTec Co 2359 | HK$189.30 | HK$150.16 | −21% |
| Lonza Group LONN | CHF 576.60 | CHF 259.80 | −55% |
| IDEXX Laboratories, Inc IDXX | $556.69 | $255.77 | −54% |
| Agilent Technologies, Inc A | $149.93 | $61.53 | −59% |
| Waters Corporation WAT | $416.15 | $121.96 | −71% |
| IQVIA Holdings IQV | $236.66 | $132.17 | −44% |
| Illumina, Inc ILMN | $215.59 | $95.51 | −56% |
| Mettler-Toledo International Inc MTD | $1,419 | $615.78 | −57% |
Compare Joinn Laboratories(China)Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Joinn Laboratories(China)Co (603127) overvalued or undervalued?
What is the fair value of 603127?
What is the quality score of 603127?
What is the revenue of Joinn Laboratories(China)Co (603127)?
What is the net profit margin of 603127?
Does Joinn Laboratories(China)Co pay a dividend?
Watch Joinn Laboratories(China)Co in the live analysis
One click puts Joinn Laboratories(China)Co on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.